ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / GANX / forecast
SER (31) IBIO (23) HYPD (38) ANVS (35) ⌘ Pro Terminal →

Gain Therapeutics Inc. (GANX) 12-Month Stock Forecast & Price Target Cone

$1.13 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.13

Gain Therapeutics Inc. (GANX) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $49.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GANX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GANX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Gain Therapeutics Inc. (NASDAQ: GANX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $1.13 (0.00% 1D, market cap $49.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, GANX ranks #447 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GANX compare to SER and IBIO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GANX carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SER (Serina Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M) and IBIO (iBio Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $49.4M). Among the 5-stock peer group, GANX leads on earnings multiple (N/A) while GANX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GANX?
▼

Per GANX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819411), Gain Therapeutics Inc. generated $52.4M in revenue (-8.1% YoY), -$20.2M in net income, and -$18.5M in free cash flow against $22.8M in total assets and $300.1K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.13 (-0.19%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk C-
Cash (7)Whales (3)SEC (13)Macro (11)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-8% Base Target
$5 Bull$1 Base$1 Bear
📬 FREE GANX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GANX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY GANX SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
49
Grade D$1.41-15.6% Next Q
Q2 (-2Q)
46
Grade D$1.19-1.7% Next Q
Q3 (-1Q)
44
Grade D$1.17-3.4% Next Q
Current
41
Grade D-$1.13-7.2% Hist 90D α
Trajectory: D (49) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GANX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GANX currently carries a cautious 41/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.59) and Max Pain ($1.19) forces dealer call-delta covering toward $4.56.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GANX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GANX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your GANX Position Size: $10,000

Shares at $1.13: 8849.6 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.81
$7,168
$-2,832 (-28.3%)
12M Consensus BaseTarget $1.04
$9,204
$-796 (-8.0%)
12M Bull Case BreakoutTarget $4.56
$40,354
+$30,354 (+303.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$469%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GANX)

  • ✓Walkthrough of GANX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GANX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -40.53%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.19H $1.19L $1.13C $1.13VOL 364.7K
RES: $2.61SUP: $1.10SMA50: $1.59SMA200: $1.85
$2.46$2.09$1.73$1.36$1.00RES $2.61SUP $1.10$1.132026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GANX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GANX Butterfly Map → + Track GANX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -8.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GANX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GANX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GANX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GANX)

Health Care Rank #447 of 1015 ⚔️ SER vs GANX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GANX vs. SER, IBIO, HYPD, ANVS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Gain Therapeutics Inc. (GANX) ranks #447 by composite RQD confidence (41/100, grade D-) and #746 by equity capitalization ($49.3M). Within this direct 5-issuer industry benchmark cohort, GANX leads on earnings valuation at N/A trailing P/E, while GANX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GANX currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GANX ACTIVE
Gain Therapeutics Inc.
D- 41/100 — — -35.0% 0.00% $49.3M Benchmark Subject
SER
Serina Therapeutics Inc.
E 31/100 — — -35.0% -4.64% $49.3M /ser-vs-ganx →
IBIO
iBio Inc.
E 23/100 — — -35.0% +4.06% $49.4M /ibio-vs-ganx →
HYPD
Hyperion DeFi Inc.
D- 38/100 — 62.7% -35.0% -7.76% $49.7M /hypd-vs-ganx →
ANVS
Annovis Bio Inc.
D- 35/100 — — -35.0% -4.42% $48.2M /anvs-vs-ganx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001819411 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Gain Therapeutics Inc. (GANX) reported GAAP revenue of $52.4M (-8.1% vs. FY2024 revenue of $57.0M , and +94843.8% cumulative change since FY2023) , GAAP net income of -$20.2M, operating cash flow of -$18.5M, and free cash flow of -$18.5M (+2.2% YoY). On the balance sheet, GANX closed FY2025 with $22.8M in total assets against $300.1K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $52.4M -$20.2M -$18.5M -$18.5M $22.8M $300.1K
FY2024 (FY) 2024-12-31 $57.0M -$20.4M -$18.9M -$18.9M $12.1M $328.3K
FY2023 (FY) 2023-12-31 $55.2K -$22.3M -$18.9M -$18.9M — —

3. GANX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GANX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Gain Therapeutics Inc. (NASDAQ: GANX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $1.13 (0.00% 1D, market cap $49.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, GANX ranks #447 in composite RQD confidence.

How does GANX compare to SER and IBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GANX carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SER (Serina Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M) and IBIO (iBio Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $49.4M). Among the 5-stock peer group, GANX leads on earnings multiple (N/A) while GANX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GANX?

Per GANX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819411), Gain Therapeutics Inc. generated $52.4M in revenue (-8.1% YoY), -$20.2M in net income, and -$18.5M in free cash flow against $22.8M in total assets and $300.1K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GANX trading relative to its 50-day, 200-day, and 52-week technical levels?

GANX last traded at $1.13 (0.00% on volume of 268,681 shares), positioning the stock -28.93% below its 50-day simple moving average ($1.59) and -38.92% below its 200-day simple moving average ($1.85). Across its 52-week range of $1.11 to $4.34, GANX sits at the 0.6% percentile with a 14-day RSI of 31.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.27).

Direct Sub-Reports: GANX RQD Cockpit GANX 12M Forecast GANX Earnings & Move GANX Dividends & DRIP GANX Insiders & 13F GANX Whale Options GANX Profit Sankey GANX News & Why
ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

GANX — Gain Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Gain Therapeutics Inc. (GANX) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.13 (0.00% 1D, market capitalization $49.3M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of 0.02x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Gain Therapeutics Inc. (GANX) is a NASDAQ-listed issuer. It operates in the Health Care sector, in the Biotechnology: Pharmaceutical Preparations industry. The FY 2025 and FY 2024 revenue are each —, and FY 2023 revenue is $0.1M ().

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Gain Therapeutics Inc. (GANX) reported $52.4M in annual revenue (up from $57.0M in FY2024, -8.1% YoY) and -$20.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($55.2K revenue, -$22.3M net income) through FY2025, GANX scaled operating cash flow to -$18.5M and free cash flow to -$18.5M, backed by $22.8M in total assets against $300.1K in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.11 – $4.34 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), GANX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can GANX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $52.4M and free cash flow of -$18.5M, how will capital allocation balance growth reinvestment against $300.1K in total debt?
  • Key Question #3: How sensitive is GANX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GANX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Gain Therapeutics Inc. (GANX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GANX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GANX Bull vs. Bear Conversation Board — What's Your Call at $1.13?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GANX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GANX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $1.30 (+15.0%)
📌 Pinned Debate

Low leverage (Debt/Equity 0.02) and cash rising to $20.8M in FY 2025 give the balance sheet room to fund operations.

Low leverage (Debt/Equity 0.02) and cash rising to $20.8M in FY 2025 give the balance sheet room to fund operations.. When you look under the hood at GANX, Fundamental Cash Engine is 7/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $4.34. My 12M target is $1.30.

RetailWhale_TX 🐂 BULL

@RiskArb_Desk Shorting a 3/20 institutional whale-flow stock at $1.13 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.94 (-16.8%)
Spot @ $1.13

Operating losses of -$18.7M against zero revenue and ROIC of -35% mean the company is not yet producing returns on the capital it consu

Careful chasing GANX at $1.13. Operating losses of -$18.7M against zero revenue and ROIC of -35% mean the company is not yet producing returns on the capital it consumes.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.94 on multiple compression.

LIVE TAPE